



MEETING AGENDA

Pharmacy and Therapeutics Committee

Virtual Meeting

May 21, 2025 12:00PM – 5:00PM

Registration: <https://teams.microsoft.com/meet/221045229711?p=de1QrGrujCNSpsDXng>

Meeting ID: 221 045 229 711 Passcode: bU3FX9ep

Dial in by phone: [+1 480-561-5941](tel:+14805615941), [909857889#](tel:+1909857889) United States, Phoenix

[Find a local number](#) Phone conference ID: 909 857 889#

TIME	TOPIC/PRESENTER
12:00 PM	Welcome & Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	Minutes Review & Vote - P&T January 15, 2025: Suzanne Berman
12:15 PM	Legislative Report Update: Suzi Berman
12:30 PM	Supplemental Rebate Drug Class Review: Clinical review by Umang Patel, PharmD, Prime Therapeutics 1. Analgesics, Long-Acting Narcotic a. Public Testimony: None 2. Antibiotics, Inhaled a. Public Testimony – Oral: i. Michelle Ratkiewicz 3. Antimigraine Agents, Other a. Public Testimony – Written: i. Mandeep Sohal 4. Antipsychotics, Atypical Long-Acting Injectable a. Public Testimony – Oral: i. Stefan Luft ii. Mandeep Sohal iii. Chung Trinh b. Public Testimony – Written: i. Carrie Bowman ii. Josie Cooper iii. Casey Hollingsworth iv. Tammy Hostetler v. Miguel Tosado 5. Antipsychotics, Oral Atypical (2nd Gen Only) a. Public Testimony – Oral: i. Amy Filleman ii. Scott Gilman b. Public Testimony – Written: i. David Delawder

MEETING AGENDA

	ii. Christine Gonzalez iii. Cindy Komar iv. Kristen Pyland v. Kristina Sabetta vi. Tabitha Salzer
	6. Colony Stimulating Factors a. Public Testimony: None
	7. COPD Agents a. Public Testimony: None
	8. Cytokine and CAM Antagonists a. Public Testimony – Oral: i. Amy Hale b. Public Testimony – Written: i. Mandeep Sohal
	9. Glucagon Agents a. Public Testimony – Written: i. Rachel Shubitz
	10. Glucocorticoids, Inhaled a. Public Testimony – Oral: i. Christine Dube
	11. Growth Hormone a. Public Testimony – Written: i. Joel Hahnke ii. Chirag Kapadia
	12. Hepatitis C Agents a. Public Testimony: None
	13. Hypoglycemics (Insulin and Related Agents) a. Public Testimony: None
	14. Hypoglycemics, Incretin Mimetics/Enhancers a. Public Testimony – Oral: i. Justen Caleca ii. Lixian Zou b. Public Testimony – Written: i. Lory Baraz ii. Edgardo Laurel
	15. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma) a. Public Testimony – Oral: i. Debby Ham ii. Carla McSpadden iii. Krystle Thai b. Public Testimony – Written: i. Christine Dube
	16. Movement Disorders

MEETING AGENDA

	a. Public Testimony – Oral: i. Ray Kong b. Public Testimony – Written: i. Mandeep Sohal 17. Multiple Sclerosis Agents a. Public Testimony – Oral: i. Shirley Quach ii. Payal Tejani b. Public Testimony – Written: i. Stephanie Niemi-Olson ii. Michael Robers iii. Naveed Vehra 18. Opioid Dependence Treatments a. Public Testimony – Oral: i. Megan Penner 19. Pancreatic Enzymes a. Public Testimony: None 20. Stimulants and Related Agents a. Public Testimony – Oral: i. Patrick Harvey b. Public Testimony – Written: i. Kristina Sabetta ii. Joseph Werther
3:15 PM	New Drug Reviews: Umang Patel 1. Alyftrek 2. Crenessity a. Public Testimony – Written: i. Ray Kong 3. Tryngolza 4. Tryvio
3:30 PM	Break & Executive Session: Nina Bandali, PharmD, Prime Therapeutics
4:45 PM	Public Therapeutic Class Votes: Hind Douiki
4:55 PM	Biosimilar Update: Suzi Berman
5:00 PM	Meeting Adjournment 2025 Meeting Dates: October 22